Immuno-oncology is a rapidly developing field in medicine.Drug combination therapies have already been studied in many clinical trials on various tumor types.In recent years,a checkpoint inhibition therapy with monocl...Immuno-oncology is a rapidly developing field in medicine.Drug combination therapies have already been studied in many clinical trials on various tumor types.In recent years,a checkpoint inhibition therapy with monoclonal antibodies targeting PD-1 and its ligand PD-L1 has been developed.Breast cancer had been examined in the field of immune-oncology relatively recently.This review focuses on clinical evidence regarding immune checkpoint inhibition for curative treatment of various breast cancer subtypes.In addition,we present the results of studies demonstrating the prognostic and predictive value of levels of tumorinfiltrating lymphocytes(CD4 and CD8),their quantitative ratios,and their correlation with regulatory genes(PD-1,PD-L1,and FOX-P3).展开更多
Aim:Neo-adjuvant chemotherapy is a common approach for the complex treatment of breast cancer(BC)and paclitaxel(PTX)is frequently included in the therapeutic regimen.However,the effect of PTX-based treatment is hard t...Aim:Neo-adjuvant chemotherapy is a common approach for the complex treatment of breast cancer(BC)and paclitaxel(PTX)is frequently included in the therapeutic regimen.However,the effect of PTX-based treatment is hard to predict precisely based on routinely used markers.As microRNAs are considered a new promising class of biomarkers,the link between miRNA expression and PTX resistance of BC cells needs to be well investigated.This study aimed at the identification of miRNAs associated with responses of BC cells to PTX.Methods:Intrinsic PTX sensitivity and miRNA profiling were assayed in five BC cell lines to identify candidate miRNAs.Selected miRNA(n.15)expressions were analyzed by real-time-quantitative polymerase chain reaction(RT-qPCR)in BC tissue samples(n.31)obtained from a diagnostic biopsy.Results were analyzed in the context of the effect of two cycles of PTX and the effect of the completed scheme of neoadjuvant therapy.The study’s design facilitated the evaluation of the effect of PTX on cells and the identification of features of the microRNA expression profiles associated exclusively with sensitivity to this drug.Results:miR-186 and miR-7 expression in BC tissues was higher in patients with better outcomes of PTX-based neoadjuvant therapy.Conclusion:High expressions of miR-186 and miR-7 are associated with good response to PTX,whereas their low expressions may be associated with resistance to PTX in BC,indicating the possibility of developing innovative test systems for the prediction of the PTX response,which can be used before the start of neo-adjuvant chemotherapy for BC.展开更多
文摘Immuno-oncology is a rapidly developing field in medicine.Drug combination therapies have already been studied in many clinical trials on various tumor types.In recent years,a checkpoint inhibition therapy with monoclonal antibodies targeting PD-1 and its ligand PD-L1 has been developed.Breast cancer had been examined in the field of immune-oncology relatively recently.This review focuses on clinical evidence regarding immune checkpoint inhibition for curative treatment of various breast cancer subtypes.In addition,we present the results of studies demonstrating the prognostic and predictive value of levels of tumorinfiltrating lymphocytes(CD4 and CD8),their quantitative ratios,and their correlation with regulatory genes(PD-1,PD-L1,and FOX-P3).
基金funded within the framework of a state assignment(121032300206-4)by the Ministry of Health of the Russian Federation.
文摘Aim:Neo-adjuvant chemotherapy is a common approach for the complex treatment of breast cancer(BC)and paclitaxel(PTX)is frequently included in the therapeutic regimen.However,the effect of PTX-based treatment is hard to predict precisely based on routinely used markers.As microRNAs are considered a new promising class of biomarkers,the link between miRNA expression and PTX resistance of BC cells needs to be well investigated.This study aimed at the identification of miRNAs associated with responses of BC cells to PTX.Methods:Intrinsic PTX sensitivity and miRNA profiling were assayed in five BC cell lines to identify candidate miRNAs.Selected miRNA(n.15)expressions were analyzed by real-time-quantitative polymerase chain reaction(RT-qPCR)in BC tissue samples(n.31)obtained from a diagnostic biopsy.Results were analyzed in the context of the effect of two cycles of PTX and the effect of the completed scheme of neoadjuvant therapy.The study’s design facilitated the evaluation of the effect of PTX on cells and the identification of features of the microRNA expression profiles associated exclusively with sensitivity to this drug.Results:miR-186 and miR-7 expression in BC tissues was higher in patients with better outcomes of PTX-based neoadjuvant therapy.Conclusion:High expressions of miR-186 and miR-7 are associated with good response to PTX,whereas their low expressions may be associated with resistance to PTX in BC,indicating the possibility of developing innovative test systems for the prediction of the PTX response,which can be used before the start of neo-adjuvant chemotherapy for BC.
